Patrick Wood
Stock Analyst at Morgan Stanley
(3.36)
# 1,049
Out of 4,667 analysts
69
Total ratings
45.45%
Success rate
6.4%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SOLV Solventum | Maintains: Equal-Weight | $60 → $73 | $68.40 | +6.73% | 3 | Nov 11, 2024 | |
| PODD Insulet | Maintains: Overweight | $234 → $317 | $266.58 | +18.91% | 5 | Nov 11, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $92 → $100 | $90.77 | +10.17% | 4 | Oct 24, 2024 | |
| EW Edwards Lifesciences | Reinstates: Equal-Weight | $70 | $69.80 | +0.29% | 7 | Oct 11, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Equal-Weight | $45 | $30.15 | +49.25% | 2 | Sep 23, 2024 | |
| COO The Cooper Companies | Maintains: Equal-Weight | $95 → $104 | $99.08 | +4.97% | 4 | Sep 10, 2024 | |
| DXCM DexCom | Maintains: Equal-Weight | $120 → $75 | $75.24 | -0.32% | 6 | Jul 26, 2024 | |
| RBOT Vicarious Surgical | Maintains: Equal-Weight | $18 → $10 | $9.03 | +10.74% | 2 | Jul 15, 2024 | |
| GKOS Glaukos | Maintains: Equal-Weight | $100 → $120 | $141.44 | -15.16% | 2 | Jul 15, 2024 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $104 → $145 | $77.20 | +87.82% | 1 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $65 → $85 | $85.50 | -0.58% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $26.32 | +40.58% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $39 → $30 | $32.33 | -7.21% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $19.38 | -7.12% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $74 → $86 | $84.90 | +1.30% | 5 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $225 → $215 | $212.25 | +1.30% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $310 → $280 | $221.29 | +26.53% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $188.18 | - | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $44.81 | -19.66% | 1 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $161.40 | - | 5 | Dec 11, 2017 |
Solventum
Nov 11, 2024
Maintains: Equal-Weight
Price Target: $60 → $73
Current: $68.40
Upside: +6.73%
Insulet
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $266.58
Upside: +18.91%
Boston Scientific
Oct 24, 2024
Maintains: Overweight
Price Target: $92 → $100
Current: $90.77
Upside: +10.17%
Edwards Lifesciences
Oct 11, 2024
Reinstates: Equal-Weight
Price Target: $70
Current: $69.80
Upside: +0.29%
Tandem Diabetes Care
Sep 23, 2024
Maintains: Equal-Weight
Price Target: $45
Current: $30.15
Upside: +49.25%
The Cooper Companies
Sep 10, 2024
Maintains: Equal-Weight
Price Target: $95 → $104
Current: $99.08
Upside: +4.97%
DexCom
Jul 26, 2024
Maintains: Equal-Weight
Price Target: $120 → $75
Current: $75.24
Upside: -0.32%
Vicarious Surgical
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $9.03
Upside: +10.74%
Glaukos
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $100 → $120
Current: $141.44
Upside: -15.16%
TransMedics Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $104 → $145
Current: $77.20
Upside: +87.82%
Jul 15, 2024
Upgrades: Equal-Weight
Price Target: $65 → $85
Current: $85.50
Upside: -0.58%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $26.32
Upside: +40.58%
Jul 15, 2024
Downgrades: Underweight
Price Target: $39 → $30
Current: $32.33
Upside: -7.21%
May 6, 2024
Upgrades: Overweight
Price Target: $16 → $18
Current: $19.38
Upside: -7.12%
Feb 12, 2024
Maintains: Equal-Weight
Price Target: $74 → $86
Current: $84.90
Upside: +1.30%
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $225 → $215
Current: $212.25
Upside: +1.30%
Dec 4, 2023
Maintains: Overweight
Price Target: $310 → $280
Current: $221.29
Upside: +26.53%
Dec 4, 2023
Upgrades: Overweight
Price Target: n/a
Current: $188.18
Upside: -
Dec 4, 2023
Initiates: Overweight
Price Target: $36
Current: $44.81
Upside: -19.66%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $161.40
Upside: -